Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by KBC Group NV

KBC Group NV boosted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 61.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 12,307 shares of the company’s stock after acquiring an additional 4,705 shares during the quarter. KBC Group NV’s holdings in Recursion Pharmaceuticals were worth $83,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in RXRX. ARK Investment Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 16.4% during the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after purchasing an additional 4,626,268 shares during the period. State Street Corp lifted its stake in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after acquiring an additional 4,120,685 shares during the period. FMR LLC boosted its holdings in shares of Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock valued at $55,116,000 after acquiring an additional 170,810 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after acquiring an additional 656,003 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Recursion Pharmaceuticals by 2.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,140,750 shares of the company’s stock valued at $14,108,000 after purchasing an additional 43,078 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on RXRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday. KeyCorp dropped their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th.

Insider Activity at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total transaction of $87,455.08. Following the completion of the transaction, the director now directly owns 7,066,113 shares in the company, valued at $53,985,103.32. This represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.75% of the stock is owned by company insiders.

Recursion Pharmaceuticals Stock Up 3.5 %

RXRX opened at $7.49 on Monday. The company has a fifty day moving average of $7.15 and a two-hundred day moving average of $6.89. The stock has a market capitalization of $2.93 billion, a price-to-earnings ratio of -4.90 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.60 and a fifty-two week high of $15.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.